Rhinitis News and Research

RSS

Rhinitis, commonly known as a runny nose, is the medical term describing irritation and inflammation of some internal areas of the nose. The primary symptom of rhinitis is nasal dripping. It is caused by chronic or acute inflammation of the mucous membrane of the nose due to viruses, bacteria or irritants.

7% of elementary school children infected with T. tonsurans: Pediatrics

Approximately 7 percent of elementary school children across the bi-state, Kansas City metropolitan area are infected with the fungus Trichophyton tonsurans, the leading cause of ringworm in the U.S., according to a new study published today in Pediatrics.

19 Apr 2010

HRV devices reduce respiratory symptoms in children: Study

Houses today are so well sealed that they can trap humidity and pollutants indoors as a result of insufficient ventilation. Recently, a team of Canadian scientists led by Dr. Tom Kovesi, a pediatric respirologist at the Children's Hospital of Eastern Ontario in Ottawa, Canada, performed a randomized double-blind, placebo controlled trial to determine whether use of heat recovery ventilators would increase home ventilation and therefore reduce the risk of lower respiratory tract illness in young children.

7 Apr 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic rhinitis.

16 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Phase III study results of Merck's allergy immunotherapy tablet

In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo

3 Mar 2010

UK pharmacists overwhelmingly prefer dispensing preservative-free drugs

MeadWestvaco Corp. announced today results from an online survey of 100 pharmacists in the UK regarding their preference for dispensing preservative-free nasal medications. The survey showed that 67 percent of UK pharmacists have a preference for dispensing a preservative-free drug. This percentage increased significantly to 84 percent after the benefits of preservative-free drugs were reviewed with these pharmacists.

24 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.

12 Feb 2010

Alcon reports 2009 fourth quarter results

Alcon, Inc. reported that global sales rose 14.5 percent to $1.72 billion for the fourth quarter of 2009, or an 8.5 percent increase excluding the impact of foreign exchange fluctuations. Reported net earnings for the fourth quarter of 2009 grew 8.0 percent to $458 million, or $1.51 per diluted share.

11 Feb 2010

Eczema in early childhood may influence behavior and mental health later in life

Eczema in early childhood may influence behavior and mental health later in life. This is a key finding of a prospective birth cohort study to which scientists of Helmholtz Zentrum München contributed.

11 Feb 2010

Eczema can lead to behavioral and psychological problems in children

11 Feb 2010

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

A joint GA²LEN /EAACI report to be published in "Allergy" and available online on 8 February reviews new data on the treatment of allergies with older antihistamines compared with newer, second-generation H1-antihistamines. The research was funded by GA²LEN, an EU-funded Network of Excellence.

10 Feb 2010

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

Phadia, the world leader in allergy blood testing diagnostics, today announced that the United States Food and Drug Administration (FDA) has cleared the ImmunoCAP® Rapid Reader II, a part of the ImmunoCAP Rapid System, used to aid in the diagnosis of allergy in the physician’s office.

27 Jan 2010

Researchers to study the impact of asthma on sleep and academic performance of young children

Bradley Hasbro Children's Research Center and Hasbro Children's Hospital researchers have received more than $2.5 million in direct costs from The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to study the impact of asthma on the sleep quality and academic performance of young children.

22 Jan 2010

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.

19 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Allergy immunotherapy, generally referred to as allergy vaccinations or shots, reduce total health care costs in children with allergic rhinitis (hay fever) by one-third, and prescription costs by 16 percent, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

11 Jan 2010

New study suggests nasal allergy may be involved in chronic sinus disease

Exposing patients with chronic sinus disease to allergens and then obtaining repeated images by X-ray or ultrasound reveals that nasal allergies may be involved in some cases of chronic sinus disease, according to a report in the December issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.

22 Dec 2009

Rhinitis News and Research

Further Reading

7% of elementary school children infected with T. tonsurans: Pediatrics

HRV devices reduce respiratory symptoms in children: Study

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Phase III study results of Merck's allergy immunotherapy tablet

UK pharmacists overwhelmingly prefer dispensing preservative-free drugs

Merck announces global sales of $27.4 billion for full-year 2009

Meda publishes 2009 year-end report

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Alcon reports 2009 fourth quarter results

Eczema in early childhood may influence behavior and mental health later in life

Eczema can lead to behavioral and psychological problems in children

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

Researchers to study the impact of asthma on sleep and academic performance of young children

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

VentiRx Pharmaceuticals completes $25 million Series A Extension

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

New study suggests nasal allergy may be involved in chronic sinus disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News